News stories about LivaNova (NASDAQ:LIVN) have been trending somewhat positive on Thursday, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. LivaNova earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.5852678354691 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
LivaNova (NASDAQ LIVN) opened at $83.31 on Thursday. The firm has a market capitalization of $3,989.99, a P/E ratio of 71.21, a PEG ratio of 2.46 and a beta of 0.83. The company has a current ratio of 2.03, a quick ratio of 1.42 and a debt-to-equity ratio of 0.04. LivaNova has a 12-month low of $45.67 and a 12-month high of $88.56.
A number of analysts have issued reports on the company. BidaskClub raised LivaNova from a “hold” rating to a “buy” rating in a research note on Friday, January 26th. Zacks Investment Research downgraded LivaNova from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 25th. ValuEngine raised LivaNova from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Needham & Company LLC lifted their price objective on LivaNova to $93.00 and gave the stock a “buy” rating in a research note on Tuesday, November 21st. Finally, Canaccord Genuity reissued a “hold” rating and set a $76.00 target price on shares of LivaNova in a research report on Tuesday, December 5th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. LivaNova has a consensus rating of “Hold” and an average price target of $79.71.
LivaNova Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.